SB-01
Degenerative Disc Disease (DDD)
Phase 3Active
Key Facts
About Spine BioPharma
Spine BioPharma is a private, pre-revenue biotech focused on a critical unmet need: non-opioid, non-surgical treatments for chronic low back pain caused by degenerative disc disease (DDD). The company's pipeline is centered on SB-01, a first-in-class, intradiscally injected therapeutic that has advanced to a Phase 3 clinical trial. Operating with a lean structure, Spine BioPharma leverages partnerships with pharmaceutical companies, scientists, and clinicians to advance its mission of improving quality of life for millions of patients suffering from debilitating spinal conditions.
View full company profileTherapeutic Areas
Other Degenerative Disc Disease (DDD) Drugs
| Drug | Company | Phase |
|---|---|---|
| CybroCell™ | FibroBiologics | Phase I / II |